![Matteo Lambertini, MD PhD on Twitter: "The #CTS5 calculator to help predicting the risk of late distant recurrence in postmenopausal patients with #EstrogenReceptor-positive early #BreastCancer is freely available online: future possible application Matteo Lambertini, MD PhD on Twitter: "The #CTS5 calculator to help predicting the risk of late distant recurrence in postmenopausal patients with #EstrogenReceptor-positive early #BreastCancer is freely available online: future possible application](https://pbs.twimg.com/media/DtmyulWUUAA2UOL.jpg)
Matteo Lambertini, MD PhD on Twitter: "The #CTS5 calculator to help predicting the risk of late distant recurrence in postmenopausal patients with #EstrogenReceptor-positive early #BreastCancer is freely available online: future possible application
![Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning - ScienceDirect Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2001037021005377-gr1.jpg)
Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning - ScienceDirect
![EBCTCG Analysis Identifies Recurrence Risk by Tumor Subgroup in Estrogen Receptor–Positive Breast Cancer - The ASCO Post EBCTCG Analysis Identifies Recurrence Risk by Tumor Subgroup in Estrogen Receptor–Positive Breast Cancer - The ASCO Post](https://ascopost.com/media/14002242/71304_table-1.jpg)
EBCTCG Analysis Identifies Recurrence Risk by Tumor Subgroup in Estrogen Receptor–Positive Breast Cancer - The ASCO Post
![Cancers | Free Full-Text | Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It? Cancers | Free Full-Text | Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?](https://pub.mdpi-res.com/cancers/cancers-12-03308/article_deploy/html/images/cancers-12-03308-g001.png?1605081361)
Cancers | Free Full-Text | Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?
Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy | PLOS ONE
![Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology](https://www.thelancet.com/cms/asset/046f5236-fe23-4fbf-b99b-5072e6b336df/gr2.jpg)
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
![Cancers | Free Full-Text | Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review Cancers | Free Full-Text | Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review](https://pub.mdpi-res.com/cancers/cancers-14-01898/article_deploy/html/images/cancers-14-01898-g001-550.jpg?1649669854)
Cancers | Free Full-Text | Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
![A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients | Scientific Reports A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-61535-9/MediaObjects/41598_2020_61535_Fig1_HTML.png)
A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients | Scientific Reports
![A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence | Scientific Reports A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51335-1/MediaObjects/41598_2019_51335_Fig1_HTML.png)
A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence | Scientific Reports
![Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer - ScienceDirect Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1879406819303534-gr1.jpg)